Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes onlyRR 0.66 [0.45, 0.98]7 studies · 1076 participantsVery low